Stem definition | Drug id | CAS RN |
---|---|---|
antibiotics, produced by Streptomyces strains | 4711 | 8025-81-8 |
Molecule | Description |
---|---|
Synonyms:
|
A macrolide antibiotic produced by Streptomyces ambofaciens. The drug is effective against gram-positive aerobic pathogens, N. gonorrhoeae, and staphylococci. It is used to treat infections caused by bacteria and Toxoplasma gondii.
|
Dose | Unit | Route |
---|---|---|
3 | g | O |
Property | Value | Reference |
---|---|---|
BA (Bioavailability) | 35 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 5.40 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 12.80 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.26 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 5.20 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
July 2, 2018 | PMDA | Sanofi KK |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Cholestasis | 122.20 | 45.36 | 38 | 1209 | 29396 | 63458379 |
Hepatocellular injury | 112.17 | 45.36 | 35 | 1212 | 27346 | 63460429 |
Rash maculo-papular | 64.34 | 45.36 | 24 | 1223 | 31872 | 63455903 |
Talipes | 53.94 | 45.36 | 11 | 1236 | 1529 | 63486246 |
Premature rupture of membranes | 50.70 | 45.36 | 13 | 1234 | 4980 | 63482795 |
Dysmorphism | 49.56 | 45.36 | 11 | 1236 | 2285 | 63485490 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Toxic epidermal necrolysis | 143.08 | 49.84 | 47 | 1330 | 21599 | 34933955 |
Hepatocellular injury | 114.34 | 49.84 | 40 | 1337 | 22171 | 34933383 |
Cholestasis | 95.93 | 49.84 | 37 | 1340 | 26911 | 34928643 |
Rash maculo-papular | 86.99 | 49.84 | 35 | 1342 | 28416 | 34927138 |
Hypertransaminasaemia | 79.63 | 49.84 | 22 | 1355 | 5584 | 34949970 |
Acute generalised exanthematous pustulosis | 71.10 | 49.84 | 21 | 1356 | 6755 | 34948799 |
Drug reaction with eosinophilia and systemic symptoms | 62.62 | 49.84 | 29 | 1348 | 32983 | 34922571 |
Rhabdomyolysis | 60.54 | 49.84 | 36 | 1341 | 68127 | 34887427 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Cholestasis | 211.06 | 39.52 | 75 | 2551 | 52034 | 79689728 |
Hepatocellular injury | 206.09 | 39.52 | 72 | 2554 | 47521 | 79694241 |
Rash maculo-papular | 144.38 | 39.52 | 58 | 2568 | 56020 | 79685742 |
Toxic epidermal necrolysis | 135.46 | 39.52 | 52 | 2574 | 44529 | 79697233 |
Drug reaction with eosinophilia and systemic symptoms | 85.93 | 39.52 | 42 | 2584 | 64202 | 79677560 |
Hypertransaminasaemia | 79.35 | 39.52 | 25 | 2601 | 11899 | 79729863 |
Acute generalised exanthematous pustulosis | 77.95 | 39.52 | 27 | 2599 | 17227 | 79724535 |
Eosinophilia | 73.96 | 39.52 | 34 | 2592 | 45311 | 79696451 |
Rhabdomyolysis | 57.39 | 39.52 | 38 | 2588 | 103093 | 79638669 |
Septic shock | 53.67 | 39.52 | 39 | 2587 | 122762 | 79619000 |
Lung disorder | 48.02 | 39.52 | 31 | 2595 | 80526 | 79661236 |
Premature rupture of membranes | 46.64 | 39.52 | 13 | 2613 | 4056 | 79737706 |
Respiratory distress | 43.77 | 39.52 | 26 | 2600 | 58313 | 79683449 |
Hepatic cytolysis | 40.03 | 39.52 | 19 | 2607 | 27132 | 79714630 |
None
Source | Code | Description |
---|---|---|
ATC | J01FA02 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS Macrolides |
ATC | J01RA04 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE COMBINATIONS OF ANTIBACTERIALS Combinations of antibacterials |
CHEBI has role | CHEBI:33281 | antibiotics |
CHEBI has role | CHEBI:36047 | antibacterial drugs |
MeSH PA | D000900 | Anti-Bacterial Agents |
MeSH PA | D000890 | Anti-Infective Agents |
MeSH PA | D000977 | Antiparasitic Agents |
MeSH PA | D000981 | Antiprotozoal Agents |
MeSH PA | D003049 | Coccidiostats |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Prophylaxis of congenital toxoplasmosis | indication | 73893000 | DOID:13336 |
None
None
None
None
None
None
ID | Source |
---|---|
D05908 | KEGG_DRUG |
N0000168428 | NUI |
CHEBI:85260 | CHEBI |
CHEMBL453514 | ChEMBL_ID |
478 | INN_ID |
DB06145 | DRUGBANK_ID |
71ODY0V87H | UNII |
9991 | RXNORM |
002766 | NDDF |
302007 | SNOMEDCT_US |
387163002 | SNOMEDCT_US |
C0037962 | UMLSCUI |
D015572 | MESH_DESCRIPTOR_UI |
6440717 | PUBCHEM_CID |
None